SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alliance Pharmaceutical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: 993racer who wrote (300)8/17/1998 2:05:00 PM
From: 993racer  Read Replies (2) of 548
 
Subj: Re: NFLD news-->what effect on Oxygent?
Date: 98-08-17 06:12:37 EDT
From: Frode1
To: EM3racer

Great news for Oxygent. The FDA was surprised at Baxter's failure in clinical trials. Northfield has scooted along with minimal trials on patients. The problems associated with the Heme based substitutes led to the FDA request that NFLD's studies be broadened to include a much larger patient population.
Another curious point about NFLD's press release is their comments regarding the number of patients they have already tried the product on. Note that they have only treated 100 patients in the last two years. That suggests that they've done next to nothing in phase III clinical trials. Another related point is that DeWooskins remark that the additional patient trials will only put them back an additional year is ludicrous. It will take much longer.
Alliance could be negatively effected if they don't do a good job of distingushing themselves from the heme based substitutes but they are well aware of this fact and they are actively addressing the issue.
What your witnessing is the dissipation of the competition. As I've contended all along is that one by one they would fall by the wayside. The timing is shaping up nicely for ALLP. I fully expect ALLP to announce phase III clinical trials commencing in late September, close to the time that I believe Baxter will kill their product. This could push Alliance to the forefront and bring in significant institutional sponsorship. The stock is incredibly cheap at these levels and should soon rectify that.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News